Sort by

Send to

Choose Destination

Selected items

Items: 20


Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators..

J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.


Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis.

Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED.

Cardiol J. 2011;18(5):503-14. Review. Erratum in: Cardiol J. 2012;19(4):442.


Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction.

Clementy N, Pierre B, Lallemand B, Marie O, Lemoine E, Cosnay P, Fauchier L, Babuty D.

Europace. 2012 Jul;14(7):968-74. doi: 10.1093/europace/eus028.


Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, Taylor AJ.

J Am Coll Cardiol. 2011 Feb 15;57(7):821-8. doi: 10.1016/j.jacc.2010.06.062.


Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.

Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C.

Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.


Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798.


Response to the Center for Medicare & Medicaid Services coverage with evidence development request for primary prevention implantable cardioverter-defibrillators: data from the OMNI study.

Sweeney MO, Sakaguchi S, Simons G, Machado C, Connett JE, Yang F; OMNI Study Investigators..

Heart Rhythm. 2012 Jul;9(7):1058-66. doi: 10.1016/j.hrthm.2012.02.027.


Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy.

Sesselberg HW, Moss AJ, McNitt S, Zareba W, Daubert JP, Andrews ML, Hall WJ, McClinitic B, Huang DT; MADIT-II Research Group..

Heart Rhythm. 2007 Nov;4(11):1395-402.


Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?

Daugherty SL, Peterson PN, Wang Y, Curtis JP, Heidenreich PA, Lindenfeld J, Vidaillet HJ, Masoudi FA; NCDR..

Am Heart J. 2009 Aug;158(2):224-9. doi: 10.1016/j.ahj.2009.05.018.


Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Ezekowitz JA, Armstrong PW, McAlister FA.

Ann Intern Med. 2003 Mar 18;138(6):445-52. Review.


Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials.

Katritsis DG, Siontis KC, Bigger JT, Kadish AH, Steinman R, Zareba W, Siontis GC, Bardy GH, Ioannidis JP.

Heart Rhythm. 2013 Feb;10(2):200-6. doi: 10.1016/j.hrthm.2012.10.039. Review.


Programming antitachycardia pacing for primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.

Saeed M, Neason CG, Razavi M, Chandiramani S, Alonso J, Natarajan S, Ip JH, Peress DF, Ramadas S, Massumi A.

J Cardiovasc Electrophysiol. 2010 Dec;21(12):1349-54. doi: 10.1111/j.1540-8167.2010.01825.x.


Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.

Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T.

Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):16-24. doi: 10.1161/CIRCOUTCOMES.108.807123.


Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States.

Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA; National Cardiovascular Data's ICD Registry..

Circ Cardiovasc Qual Outcomes. 2011 Sep;4(5):549-56. doi: 10.1161/CIRCOUTCOMES.110.959205.


Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death.

Curtis LH, Al-Khatib SM, Shea AM, Hammill BG, Hernandez AF, Schulman KA.

JAMA. 2007 Oct 3;298(13):1517-24.


Use of a screening tool improves appropriate referral to an electrophysiologist for implantable cardioverter-defibrillators for primary prevention of sudden cardiac death.

Gravelin LM, Yuhas J, Remetz M, Radford M, Foley J, Lampert R.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):152-6. doi: 10.1161/CIRCOUTCOMES.110.956987.


Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis.

Amin MS, Fox AD, Kalahasty G, Shepard RK, Wood MA, Ellenbogen KA.

J Cardiovasc Electrophysiol. 2008 Dec;19(12):1275-80. doi: 10.1111/j.1540-8167.2008.01258.x.

Items per page

Supplemental Content

Support Center